Literature DB >> 19184307

Prognostic factors and treatment outcomes of retinoblastoma in pediatric patients: a single-institution study.

La-Ongsri Atchaneeyasakul1,2, Chutima Wongsiwaroj3, Mongkol Uiprasertkul4, Kleebsabai Sanpakit5, Kullathorn Thephamongkhol6, Adisak Trinavarat3.   

Abstract

PURPOSE: Since 1997, our institute has used neoadjuvant chemotherapy for intraocular retinoblastoma. However, some of the patients showed signs of recurrence months to years later. We therefore attempted to determine the prognostic factors of treatment outcomes and survival in our patients.
METHODS: We reviewed 90 patients treated from 1997 to 2006. The following information was recorded: demographic and ophthalmological data, clinical classification, histopathological data, and treatment methods and outcomes.
RESULTS: Enucleation was avoided in two of 57 eyes in the unilateral group. Sixteen of 54 eyes in the bilateral group were salvaged by systemic chemotherapy with local treatment. There was no difference in histopathological findings between the two groups. Nine of 57 patients in the unilateral group demonstrated poor outcomes, compared with four of 27 in the bilateral group. Significant poor prognostic factors for survival were optic nerve head invasion, orbital involvement, abnormal results on bone marrow aspiration, lumbar puncture, bone scan, and group E or F classification.
CONCLUSIONS: The 15% mortality rate in our patients is slightly higher than that reported in developed countries. Delayed diagnosis and treatment is the main cause of avoidable deaths. Improving education of both clinicians and parents would increase survival rates in this potentially fatal disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184307     DOI: 10.1007/s10384-008-0614-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  14 in total

1.  Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution.

Authors:  F Khelfaoui; P Validire; A Auperin; E Quintana; J Michon; H Pacquement; L Desjardins; B Asselain; P Schlienger; P Vielh
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

2.  Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project.

Authors:  A MacCarthy; G J Draper; Eva Steliarova-Foucher; J E Kingston
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

3.  Retinoblastoma in Turkey: survival and clinical characteristics 1981-2004.

Authors:  Alp Ozkan; Halit Pazarli; Tiraje Celkan; Serap Karaman; Hilmi Apak; Gültekin Kaner; Omer Uzel; Inci Yildiz
Journal:  Pediatr Int       Date:  2006-08       Impact factor: 1.524

4.  Chemotherapy plus local treatment in the management of intraocular retinoblastoma.

Authors:  A L Murphree; J G Villablanca; W F Deegan; J K Sato; M Malogolowkin; A Fisher; R Parker; E Reed; C J Gomer
Journal:  Arch Ophthalmol       Date:  1996-11

5.  [Intraocular retinoblastoma: new therapeutic options].

Authors:  S M Imhof; A C Moll; A Y Schouten-van Meeteren
Journal:  Ned Tijdschr Geneeskd       Date:  2001-11-10

6.  Retinoblastoma in Taiwan: the effect of a government-sponsored national health insurance program on the treatment and survival of patients with retinoblastoma.

Authors:  Wei-Wen Su; Ling-Yuh Kao
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2006 Nov-Dec       Impact factor: 1.402

7.  Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K Baez; J R Cater; P De Potter
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

8.  Intraocular retinoblastoma group V: an analysis of prognostic factors.

Authors:  C M Rubin; L L Robison; J D Cameron; W G Woods; M E Nesbit; W Krivit; T H Kim; R D Letson; N K Ramsay
Journal:  J Clin Oncol       Date:  1985-05       Impact factor: 44.544

9.  Survival rate and risk factors for patients with retinoblastoma in Japan. The Committee for the National Registry of Retinoblastoma.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  1992       Impact factor: 2.447

10.  New retinoblastoma tumor formation in children initially treated with systemic carboplatin.

Authors:  Thomas C Lee; Naomi I Hayashi; Ira J Dunkel; Katherine Beaverson; Danielle Novetsky; David H Abramson
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

View more
  9 in total

1.  Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma.

Authors:  Aman Khurana; Christina A Eisenhut; Wenshuai Wan; Katayoon B Ebrahimi; Chirag Patel; Joan M O'Brien; Kristen Yeom; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2012-11-18       Impact factor: 5.315

2.  Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.

Authors:  Erin M Sullivan; Matthew W Wilson; Catherine A Billups; Jianrong Wu; Thomas E Merchant; Rachel C Brennan; Barrett G Haik; Barry Shulkin; Tammy M Free; Vickie Given; Carlos Rodriguez-Galindo; Ibrahim Qaddoumi
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

3.  Correlation of apparent diffusion coefficient at 3T with prognostic parameters of retinoblastoma.

Authors:  A A K Abdel Razek; S Elkhamary; S Al-Mesfer; H M Alkatan
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

4.  Correlation between conventional MR imaging combined with diffusion-weighted imaging and histopathologic findings in eyes primarily enucleated for advanced retinoblastoma: a retrospective study.

Authors:  Yanfen Cui; Ran Luo; Ruifen Wang; Huanhuan Liu; Caiyuan Zhang; Zhongyang Zhang; Dengbin Wang
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

5.  Correlation between clinical presentations, radiological findings and high risk histopathological features of primary enucleated eyes with advanced retinoblastoma at Queen Sirikit National Institute of Child Health: 5 years result.

Authors:  Supawan Surukrattanaskul; Bungornrat Keyurapan; Nutsuchar Wangtiraumnuay
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

6.  Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.

Authors:  Duangnate Rojanaporn; Taweevat Attaseth; Wimwipa Dieosuthichat; Kitikul Leelawongs; Samart Pakakasama; Usanarat Anurathapan; Ekachat Chanthanaphak; Sirintara Singhara Na Ayudhaya; Rangsima Aroonroch; Suradej Hongeng
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

7.  Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma.

Authors:  Saerom Choi; Jung Woo Han; Hyosun Kim; Beom Sik Kim; Dong Joon Kim; Sung Chul Lee; Chuhl Joo Lyu
Journal:  Korean J Pediatr       Date:  2013-06-21

Review 8.  Retinoblastoma in Asia.

Authors:  Mukesh Jain; Duangnate Rojanaporn; Bhavna Chawla; Gangadhar Sundar; Lingam Gopal; Vikas Khetan
Journal:  Eye (Lond)       Date:  2018-11-01       Impact factor: 3.775

9.  Retinoblastoma Survival Following Primary Enucleation by AJCC Staging.

Authors:  Junyang Zhao; Zhaoxun Feng; Gareth Leung; Brenda L Gallie
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.